GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovoRx Inc (NAS:RNXT) » Definitions » Market Cap

RenovoRx (RenovoRx) Market Cap : $30.18 Mil (As of May. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is RenovoRx Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). RenovoRx's share price for the quarter that ended in Mar. 2024 was $1.34. RenovoRx's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 16.87 Mil. Therefore, RenovoRx's market cap for the quarter that ended in Mar. 2024 was $22.60 Mil.

RenovoRx's quarterly market cap increased from Sep. 2023 ($14.22 Mil) to Dec. 2023 ($24.49 Mil) but then declined from Dec. 2023 ($24.49 Mil) to Mar. 2024 ($22.60 Mil).

RenovoRx's annual market cap declined from Dec. 2021 ($43.24 Mil) to Dec. 2022 ($21.38 Mil) but then increased from Dec. 2022 ($21.38 Mil) to Dec. 2023 ($24.49 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. RenovoRx's Enterprise Value for Today is $25.79 Mil.


RenovoRx Market Cap Historical Data

The historical data trend for RenovoRx's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovoRx Market Cap Chart

RenovoRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
- - 43.24 21.38 24.49

RenovoRx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.82 24.17 14.22 24.49 22.60

Competitive Comparison of RenovoRx's Market Cap

For the Biotechnology subindustry, RenovoRx's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RenovoRx's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovoRx's Market Cap distribution charts can be found below:

* The bar in red indicates where RenovoRx's Market Cap falls into.



RenovoRx Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

RenovoRx's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$2.29*10.6936
=$24.49

RenovoRx's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$1.34*16.866
=$22.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RenovoRx  (NAS:RNXT) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


RenovoRx Market Cap Related Terms

Thank you for viewing the detailed overview of RenovoRx's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


RenovoRx (RenovoRx) Business Description

Traded in Other Exchanges
N/A
Address
4546 El Camino Real, Suite B1, Los Altos, CA, USA, 94022
RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 pancreatic cancer clinical trial for its lead product candidate RenovoGem.
Executives
Angela Nelms officer: Chief Operating Officer C/O RENOVORX, INC., 4546 EL CAMINO REAL, SUITE B1, LOS ALTOS CA 94022
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
James M Ahlers officer: Chief Financial Officer 2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Ramtin Agah director, officer: Chief Medical Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Shaun Bagai director, officer: Chief Executive Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Bank Of The West 10 percent owner PO BOX 60078, LOS ANGELES CA 90060
Una S Ryan director 329 HAMMOND STREET, CHESTNUT HILL MA 02467
David Diamond director 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Laurence Marton director 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kirsten Angela Macfarlane director 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Christopher John Lehman officer: Chief Financial Officer 65 OAK RIDGE ROAD, BERKELEY, BERKELEY CA 94705
Paul Manners officer: Chief Financial Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kamran Najmabadi 10 percent owner 3114 DAVID AVE., PALO ALTO CA 94303
Najmabadi Family Trust Dated April 22, 2021 10 percent owner 3114 DAVID AVE., PALO ALTO CA 94303

RenovoRx (RenovoRx) Headlines

From GuruFocus

RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023

By Business Wire Business Wire 03-01-2023